University Of Maryland, Baltimore Grants Spherix Exclusive Option To License Anthrax Based Ovarian Cancer Drug Prag-Pas; Spherix Has Until Early December Of 2019 To Complete Its Due Diligence And Execute A License Agreement For Commercial Development